ADOCIA
Innovative medicine for everyone, everywhere (diabetes, metabolic diseases).
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | €9.7m | Private Placement VC | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 72 % | 693 % | (81 %) | 334 % | 18 % | 81 % | (31 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1249 %) | (10 %) | (640 %) | (74 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1576 %) | (60 %) | (984 %) | (100 %) | (85 %) | (10 %) | (69 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Adocia is a clinical-stage biotechnology company specializing in the development of innovative formulations for protein delivery, primarily targeting diabetes treatment. The company operates in the healthcare and biotechnology sectors, focusing on creating advanced injectable treatments. Adocia customizes its proprietary BioChaperone technology to enhance the efficacy and safety of therapeutic proteins. The company serves pharmaceutical and healthcare clients, aiming to improve patient outcomes through innovative drug formulations. Adocia generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The business model is centered on research and development, leveraging its extensive portfolio of clinical-stage products to attract strategic collaborations and funding.
Keywords: biotechnology, protein delivery, diabetes treatment, BioChaperone, injectable treatments, clinical-stage, pharmaceutical partnerships, innovative formulations, healthcare, therapeutic proteins.